Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Maplirpacept in Japanese Participants with Lymphoma or Multiple Myeloma
NCT05567887Phase 1Completed
- Sponsor
- Pfizer
- Start
- Nov 2022
- Primary completion
- Oct 2024
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of maplirpacept in lymphoma and multiple myeloma (MM), sponsored by Pfizer. Primary endpoint: Dose Limiting Toxicity up to 21 days. Started Nov 2022; status: completed.
02
Drugs
maplirpacept
03
Conditions
lymphomamultiple myeloma (MM)
Beyond the preview
Go deeper on NCT05567887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05567887.